Clobazam

Clinical Information

MEDTOX Laboratories is excited to announce the addition of a new quantitative test designed to monitor clobazam and its primary active metabolite, desmethylclobazam.

As of October 2011, clobazam is approved in the United States for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy in adults and in children over the age of two. Outside of the United States clobazam is approved for adjunctive therapy for epilepsy and for the treatment of anxiety.

The MEDTOX Laboratories’ test for clobazam and desmethylclobazam is a fully validated quantitative procedure with a detection limit of 10 ng/mL for both analytes. The method utilizes a state of the art high performance liquid chromatography – tandem mass spectrometry (LC-MS/MS) technique.

<table>
<thead>
<tr>
<th>Test #</th>
<th>2837</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Clobazam, desmethylclobazam, Frisium, Onfi, Urbanol</td>
</tr>
<tr>
<td>Specimen</td>
<td>Plasma, Serum, Urine</td>
</tr>
<tr>
<td>Volume</td>
<td>3 ml</td>
</tr>
<tr>
<td>Handling</td>
<td>Samples may be stored ambient or refrigerated for up to 1 week. Samples may be shipped ambient, refrigerated or frozen.</td>
</tr>
</tbody>
</table>

Assay Parameters

Methodology

Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS)

CPT Code

82542

Reporting Limit

10 ng/mL

Reference Range

Clobazam: 30 – 300 ng/mL
Desmethylclobazam: 300 – 3000 ng/mL

Critical Values

Not Established